Although this approach provides valuable information on the potential role of GFAP and S100B in AD pathogenesis and progression, a novel meta-analysis limited to techniques which measure absolute levels of the specific analytes in blood, particularly given the considerable number of recent publications reporting such results, is required in preparation for future clinical implementation. Here, GFAP is linked to Alzheimer disease.